US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

24.03

-0.2000-0.83%

Volume:169.04K

Turnover:4.11M

Market Cap:1.33B

PE:-9.55

High:24.72

Open:24.33

Low:23.74

Close:24.23

52wk High:53.65

52wk Low:22.45

Shares:55.25M

Float Shares:37.25M

Volume Ratio:0.34

T/O Rate:0.45%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5172

EPS(LYR):-3.0510

ROE:-37.35%

ROA:-21.79%

PB:2.93

PE(LYR):-7.88

Loading ...

Overview Company News Filings

Maze Therapeutics Says Phase 2 Trial of Kidney Disease Therapy Shows Over 35% Protein Marker Reduction

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma

BUZZ-Maze Therapeutics rises as kidney disease drug shows positive results in trial

Maze Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs

Earnings Flash (MAZE) Maze Therapeutics Posts Q4 Net Loss $0.65 a Share, vs. FactSet Est of $0.72 Loss

MT Newswires Live

Maze Therapeutics Q4 EPS $(0.65) Beats $(0.71) Estimate

Benzinga Earnings

Maze Therapeutics announces positive Phase 2 HORIZON topline data; week 12 uACR drops 35.6% in broad APOL1-mediated kidney disease patients

Maze Therapeutics Inc - to Advance Mze829 to Pivotal Program in Amkd

THOMSON REUTERS

Maze Therapeutics Inc - 50% of Patients Achieve >30% Uacr Reduction; Mze829 Well-Tolerated

THOMSON REUTERS

Maze Therapeutics Announces Positive Topline Data From Phase 2 Horizon Trial of Mze829 Demonstrating the First Clinical Proof-of-Concept in Patients With Broad Apol1-Mediated Kidney Disease

THOMSON REUTERS

Maze Therapeutics Inc Q4 Pretax Profit USD -34.568 Million VS. Ibes Estimate USD -34.7 Million

THOMSON REUTERS

Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 735,106 in common shares

Maze Therapeutics Initiated at Buy by Truist Securities

Maze Therapeutics Is Maintained at Outperform by Wedbush

Wedbush Raises Price Target on Maze Therapeutics to $58 From $43, Keeps Outperform Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/MAZE/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MAZE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":24.03,"timestamp":1789581050236,"preClose":24.23,"halted":0,"volume":169043,"delay":0,"changeRate":-0.008254230293025145,"floatShares":37250300,"shares":55248700,"eps":-2.517242,"marketStatus":"Trading","change":-0.2,"latestTime":"09-16 13:50:51 EDT","open":24.33,"high":24.72,"low":23.74,"amount":4112552.48292,"amplitude":0.040446,"askPrice":24.11,"askSize":260,"bidPrice":23.93,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-2.517242,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":24.23,"postHourTrading":{"tag":"盘后","latestPrice":24.23,"preClose":24.23,"latestTime":"16:10 EDT","volume":5696,"amount":138014.56,"timestamp":1789503007887,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.344913,"impliedVol":0.8551,"impliedVolPercentile":0.7291},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MAZE\",,,,,undefined,":{"symbol":"MAZE","floatShares":37250300,"roa":"-21.79%","roe":"-37.35%","lyrEps":-3.051003,"volumeRatio":0.344913,"shares":55248700,"dividePrice":0,"high":24.72,"amplitude":0.040446,"preClose":24.23,"low":23.74,"week52Low":22.4463,"pbRate":"2.93","psRate":"66.38","week52High":53.65,"institutionHeld":0,"latestPrice":24.03,"committee":-0.824561,"eps":-2.517242,"divideRate":0,"volume":169043,"delay":0,"ttmEps":-2.517242,"open":24.33,"prevYearClose":41.43,"prevWeekClose":24.6,"prevMonthClose":26.57,"prevQuarterClose":29.84,"fiveDayClose":24.58,"twentyDayClose":29.13,"sixtyDayClose":25.57},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MAZE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"MAZE","fiscalQuarterEnding":"2026/06","expectedEps":-0.76,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.76},{"market":"US","date":"2026-05-12","symbol":"MAZE","fiscalQuarterEnding":"2026/03","expectedEps":-0.43,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.45},{"market":"US","date":"2026-03-25","symbol":"MAZE","fiscalQuarterEnding":"2025/12","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"pre","actualEps":-0.65},{"market":"US","date":"2025-11-06","symbol":"MAZE","fiscalQuarterEnding":"2025/09","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2025-08-12","symbol":"MAZE","fiscalQuarterEnding":"2025/06","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.77}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MAZE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MAZE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4167,"buy":0.5833,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5833,"analysts":12,"updateTime":1773806400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MAZE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MAZE","date":"2026-09-15","current":-9.546162,"percent":0.549261,"low":-19.775245,"twenty":-14.39032,"median":-10.75722,"eighty":9.105023,"high":14.99285,"avg":-5.107183,"sd":10.951866,"marketCap":1370397974},"quantilePoints":[{"date":"2025-01-31","current":12.681398,"twenty":12.46124,"median":12.543799,"eighty":12.626358,"marketCap":700431648},{"date":"2025-02-07","current":10.303636,"twenty":10.343265,"median":11.88881,"eighty":12.594654,"marketCap":569100714},{"date":"2025-02-14","current":8.972089,"twenty":9.94063,"median":10.40271,"eighty":12.302722,"marketCap":495555390},{"date":"2025-02-21","current":9.645788,"twenty":9.645788,"median":10.220414,"eighty":11.88881,"marketCap":532765822},{"date":"2025-02-28","current":10.081711,"twenty":9.495197,"median":10.081711,"eighty":10.604819,"marketCap":556843160},{"date":"2025-03-07","current":9.29705,"twenty":9.29705,"median":9.788453,"eighty":10.501783,"marketCap":513503951},{"date":"2025-03-14","current":8.956237,"twenty":8.972089,"median":9.582381,"eighty":10.303636,"marketCap":494679851},{"date":"2025-03-21","current":9.479345,"twenty":8.972089,"median":9.534826,"eighty":10.271932,"marketCap":523572656},{"date":"2025-03-28","current":8.93246,"twenty":8.956237,"median":9.495197,"eighty":10.168896,"marketCap":493366542},{"date":"2025-04-04","current":7.814885,"twenty":8.89283,"median":9.443679,"eighty":10.137192,"marketCap":408179251},{"date":"2025-04-11","current":6.372653,"twenty":8.695317,"median":9.384234,"eighty":10.081711,"marketCap":332850033},{"date":"2025-04-17","current":6.858987,"twenty":8.362362,"median":9.29705,"eighty":9.98026,"marketCap":358251746},{"date":"2025-04-25","current":6.456504,"twenty":7.783022,"median":9.224877,"eighty":9.897831,"marketCap":337229638},{"date":"2025-05-02","current":8.879789,"twenty":7.580103,"median":8.972089,"eighty":9.731387,"marketCap":463800243},{"date":"2025-05-09","current":8.40184,"twenty":7.63209,"median":8.956237,"eighty":9.655299,"marketCap":438836491},{"date":"2025-05-16","current":7.799992,"twenty":7.63958,"median":8.89283,"eighty":9.626766,"marketCap":405123785},{"date":"2025-05-23","current":8.575775,"twenty":7.65241,"median":8.850167,"eighty":9.590307,"marketCap":445417178},{"date":"2025-05-30","current":10.26226,"twenty":7.715941,"median":8.87535,"eighty":9.631522,"marketCap":533011510},{"date":"2025-06-06","current":11.248853,"twenty":7.782471,"median":8.89283,"eighty":9.769431,"marketCap":584254194},{"date":"2025-06-13","current":11.425934,"twenty":7.799992,"median":8.956237,"eighty":10.149874,"marketCap":593451599},{"date":"2025-06-20","current":9.494909,"twenty":7.805949,"median":9.034945,"eighty":10.238649,"marketCap":493156089},{"date":"2025-06-27","current":10.742908,"twenty":7.871903,"median":9.097801,"eighty":10.238649,"marketCap":557975894},{"date":"2025-07-03","current":9.697287,"twenty":7.967493,"median":9.217791,"eighty":10.255514,"marketCap":503667409},{"date":"2025-07-11","current":13.188311,"twenty":8.01948,"median":9.285161,"eighty":10.297295,"marketCap":684987676},{"date":"2025-07-18","current":14.385715,"twenty":8.08904,"median":9.384234,"eighty":10.584212,"marketCap":747179651},{"date":"2025-07-25","current":13.871337,"twenty":8.197097,"median":9.417731,"eighty":10.84241,"marketCap":720463380},{"date":"2025-08-01","current":12.437825,"twenty":8.267679,"median":9.479345,"eighty":11.289329,"marketCap":646008198},{"date":"2025-08-08","current":11.231989,"twenty":8.274387,"median":9.503122,"eighty":11.660356,"marketCap":583378251},{"date":"2025-08-15","current":-4.846264,"twenty":8.197097,"median":9.495197,"eighty":11.50014,"marketCap":585409301},{"date":"2025-08-22","current":-4.802702,"twenty":7.843394,"median":9.46183,"eighty":11.412442,"marketCap":580147195},{"date":"2025-08-29","current":-5.180239,"twenty":7.675693,"median":9.408012,"eighty":11.34667,"marketCap":625752114},{"date":"2025-09-05","current":-5.459761,"twenty":7.605258,"median":9.384234,"eighty":11.299448,"marketCap":659517295},{"date":"2025-09-12","current":-9.002797,"twenty":7.051844,"median":9.285161,"eighty":11.248853,"marketCap":1087501923},{"date":"2025-09-19","current":-8.523616,"twenty":6.791906,"median":9.217791,"eighty":11.231989,"marketCap":1029618756},{"date":"2025-09-26","current":-9.565472,"twenty":6.372653,"median":9.072896,"eighty":11.223556,"marketCap":1155470793},{"date":"2025-10-03","current":-9.619925,"twenty":-4.846264,"median":8.956237,"eighty":11.080205,"marketCap":1162048426},{"date":"2025-10-10","current":-10.440341,"twenty":-4.897086,"median":8.912645,"eighty":10.903124,"marketCap":1261151423},{"date":"2025-10-17","current":-10.327806,"twenty":-5.035032,"median":8.87091,"eighty":10.852529,"marketCap":1247557649},{"date":"2025-10-24","current":-10.854179,"twenty":-5.43435,"median":8.743704,"eighty":10.801935,"marketCap":1311141431},{"date":"2025-10-31","current":-12.059392,"twenty":-5.764695,"median":8.710535,"eighty":10.776638,"marketCap":1456726366},{"date":"2025-11-07","current":-10.301208,"twenty":-8.440123,"median":8.622163,"eighty":10.742908,"marketCap":1299301692},{"date":"2025-11-14","current":-12.147078,"twenty":-8.530877,"median":8.52824,"eighty":10.604819,"marketCap":1532123096},{"date":"2025-11-21","current":-13.570087,"twenty":-9.148004,"median":8.467465,"eighty":10.501783,"marketCap":1711608623},{"date":"2025-11-28","current":-14.401765,"twenty":-9.516102,"median":8.389744,"eighty":10.458575,"marketCap":1816509011},{"date":"2025-12-05","current":-16.252058,"twenty":-9.864597,"median":8.267679,"eighty":10.366822,"marketCap":2049888314},{"date":"2025-12-12","current":-15.096102,"twenty":-10.151143,"median":8.122944,"eighty":10.312226,"marketCap":1904086399},{"date":"2025-12-19","current":-15.496681,"twenty":-10.373183,"median":7.957431,"eighty":10.278273,"marketCap":1954611815},{"date":"2025-12-26","current":-16.053676,"twenty":-10.591356,"median":7.799992,"eighty":10.266129,"marketCap":2024866203},{"date":"2026-01-02","current":-15.805699,"twenty":-10.832398,"median":7.756189,"eighty":10.248768,"marketCap":1993588564},{"date":"2026-01-09","current":-14.859569,"twenty":-11.164921,"median":7.639287,"eighty":10.225157,"marketCap":1874252343},{"date":"2026-01-16","current":-15.187663,"twenty":-11.722514,"median":7.479482,"eighty":10.213352,"marketCap":1915635065},{"date":"2026-01-23","current":-17.625471,"twenty":-12.065201,"median":7.127309,"eighty":10.196366,"marketCap":2223118312},{"date":"2026-01-30","current":-17.167667,"twenty":-12.419472,"median":6.955415,"eighty":10.162555,"marketCap":2165374980},{"date":"2026-02-06","current":-16.767088,"twenty":-13.567798,"median":6.791906,"eighty":10.126096,"marketCap":2114849563},{"date":"2026-02-13","current":-17.945934,"twenty":-14.175152,"median":6.511006,"eighty":10.056348,"marketCap":2263538645},{"date":"2026-02-20","current":-17.182927,"twenty":-14.401765,"median":6.360075,"eighty":9.954897,"marketCap":2167299757},{"date":"2026-02-27","current":-17.48813,"twenty":-14.737488,"median":-4.831743,"eighty":9.883564,"marketCap":2205795312},{"date":"2026-03-06","current":-17.282118,"twenty":-15.149512,"median":-4.864415,"eighty":9.832206,"marketCap":2179810813},{"date":"2026-03-13","current":-19.775245,"twenty":-15.332634,"median":-4.897086,"eighty":9.697287,"marketCap":2494271379},{"date":"2026-03-20","current":-18.857728,"twenty":-15.469975,"median":-4.962429,"eighty":9.697287,"marketCap":2378544116},{"date":"2026-03-27","current":-12.021519,"twenty":-15.550091,"median":-5.100375,"eighty":9.693343,"marketCap":1576261545},{"date":"2026-04-02","current":-11.013091,"twenty":-15.507363,"median":-5.260102,"eighty":9.683007,"marketCap":1444036514},{"date":"2026-04-10","current":-10.569535,"twenty":-15.475316,"median":-5.486987,"eighty":9.652715,"marketCap":1385877385},{"date":"2026-04-17","current":-10.186635,"twenty":-15.415039,"median":-5.764695,"eighty":9.626766,"marketCap":1335671640},{"date":"2026-04-24","current":-10.959561,"twenty":-15.395201,"median":-7.129635,"eighty":9.621519,"marketCap":1437017594},{"date":"2026-05-01","current":-11.209856,"twenty":-15.384518,"median":-8.456458,"eighty":9.590184,"marketCap":1469836362},{"date":"2026-05-08","current":-10.741725,"twenty":-15.342553,"median":-8.527247,"eighty":9.573739,"marketCap":1408454934},{"date":"2026-05-15","current":-11.93693,"twenty":-15.289905,"median":-9.002797,"eighty":9.561199,"marketCap":1462775248},{"date":"2026-05-22","current":-11.629812,"twenty":-15.205975,"median":-9.258724,"eighty":9.520559,"marketCap":1425140470},{"date":"2026-05-29","current":-11.92338,"twenty":-15.178506,"median":-9.458383,"eighty":9.511048,"marketCap":1461114890},{"date":"2026-06-05","current":-11.471737,"twenty":-15.158668,"median":-9.619925,"eighty":9.501537,"marketCap":1405769629},{"date":"2026-06-12","current":-10.880085,"twenty":-15.117466,"median":-9.821399,"eighty":9.495024,"marketCap":1333267337},{"date":"2026-06-18","current":-11.218817,"twenty":-15.001489,"median":-9.973866,"eighty":9.488683,"marketCap":1374776283},{"date":"2026-06-26","current":-12.203399,"twenty":-14.845835,"median":-10.113627,"eighty":9.465333,"marketCap":1495428952},{"date":"2026-07-02","current":-13.463484,"twenty":-14.807685,"median":-10.175262,"eighty":9.440942,"marketCap":1649842230},{"date":"2026-07-10","current":-14.642273,"twenty":-14.807685,"median":-10.243922,"eighty":9.423562,"marketCap":1794293361},{"date":"2026-07-17","current":-12.268888,"twenty":-14.735962,"median":-10.345957,"eighty":9.406427,"marketCap":1503454015},{"date":"2026-07-24","current":-12.506,"twenty":-14.713835,"median":-10.387794,"eighty":9.396916,"marketCap":1532510277},{"date":"2026-07-31","current":-12.478902,"twenty":-14.649742,"median":-10.467027,"eighty":9.384234,"marketCap":1529189561},{"date":"2026-08-07","current":-12.88538,"twenty":-14.642273,"median":-10.571027,"eighty":9.336679,"marketCap":1579000296},{"date":"2026-08-14","current":-11.503614,"twenty":-14.638297,"median":-10.649147,"eighty":9.29705,"marketCap":1536767732},{"date":"2026-08-21","current":-12.029624,"twenty":-14.610658,"median":-10.685878,"eighty":9.273272,"marketCap":1607037430},{"date":"2026-08-28","current":-11.892404,"twenty":-14.448066,"median":-10.740929,"eighty":9.231962,"marketCap":1588706204},{"date":"2026-09-04","current":-10.75722,"twenty":-14.401765,"median":-10.762812,"eighty":9.217791,"marketCap":1437056976},{"date":"2026-09-11","current":-10.32061,"twenty":-14.401765,"median":-10.762812,"eighty":9.129021,"marketCap":1378730349},{"date":"2026-09-15","current":-10.258238,"twenty":-14.39032,"median":-10.75722,"eighty":9.105023,"marketCap":1370397974}],"updateTime":1789581051456},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MAZE\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622078469","title":"Maze Therapeutics Says Phase 2 Trial of Kidney Disease Therapy Shows Over 35% Protein Marker Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078469","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078469?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:45","pubTimestamp":1774439143,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) said Wednesday its experimental oral medication demonstrated a 35.6% average reduction in a key marker of kidney damage during a phase 2 clinical trial.According to the compan","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622078483","title":"BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078483","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078483?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:45","pubTimestamp":1774439135,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Arm, Destiny Tech100, Terns PharmaWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL6N40D0SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RKLZ","LU2087621335.USD","MRK","NEM","ARE","XOMZ","XOMO","LU2324357040.USD","RKLX","ARMU","ARM","IE00B19Z3581.USD","XOMX","IE00BMPRXN33.USD","BEAM","LU0122376428.USD","ASTX","TERN","ASTN","NEMG","DXYZ","ARMG","SIDU","JPMO","LU0861579265.USD","LU2237443382.USD","DKUP","NWMX","UFO","LU0868494708.USD","ONON","LU1032466523.USD","ARMW","DRAY","IE00B19Z3B42.SGD","LU1066053197.SGD","MAZE","LU1023059063.AUD","DKNG","LU1934455194.USD","LU1267930813.SGD","ADMA","DKNX","SATL","DVN"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622020928","title":"BUZZ-Maze Therapeutics rises as kidney disease drug shows positive results in trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2622020928","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622020928?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:15","pubTimestamp":1774437313,"startTime":"0","endTime":"0","summary":"BUZZ-Maze Therapeutics rises as kidney disease drug shows positive results in trial** Shares of biotech firm Maze Therapeutics MAZE.O rise 3.1% to $50.50 premarket** Co says its experimental drug MZE829 reduced protein in urine, a key sign of kidney damage, in a midstage study** Drug targets APOL1mediated kidney disease, an inherited kidney condition that can lead to kidney failure** Study showed an average 35.6% drop in urine protein after 12 weeks; about half of patients saw drops of over 30%, co says** Adds larger reductions were seen in patients with a severe kidney scarring condition and those without diabetes** Co says it plans a larger, latestage study of MZE829 following the results** As of last close, stock was up ~18% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D105:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622549020","title":"Maze Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2622549020","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622549020?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:10","pubTimestamp":1774437021,"startTime":"0","endTime":"0","summary":"Maze Therapeutics reports bigger-than-expected Q4loss on higher R&D costsOverviewUS biopharmaceutical firm's Q4 net loss missed analyst expectations, income from operations also missedPretax profit fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL1N40D0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622020399","title":"Earnings Flash (MAZE) Maze Therapeutics Posts Q4 Net Loss $0.65 a Share, vs. FactSet Est of $0.72 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2622020399","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622020399?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:07","pubTimestamp":1774436852,"startTime":"0","endTime":"0","summary":"Earnings Flash (MAZE) Maze Therapeutics Posts Q4 Net Loss $0.65 a Share, vs. FactSet Est of $0.72 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622102085","title":"Maze Therapeutics Q4 EPS $(0.65) Beats $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622102085","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622102085?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:05","pubTimestamp":1774436753,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.71) by 8.45 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51451848/maze-therapeutics-q4-eps-0-65-beats-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622221027","title":"Maze Therapeutics announces positive Phase 2 HORIZON topline data; week 12 uACR drops 35.6% in broad APOL1-mediated kidney disease patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2622221027","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622221027?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436419,"startTime":"0","endTime":"0","summary":"Maze Therapeutics announces positive Phase 2 HORIZON topline data; week 12 uACR drops 35.6% in broad APOL1-mediated kidney disease patients. Maze Therapeutics announced positive topline data from the Phase 2 open-label HORIZON trial of MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, in patients with broad APOL1-mediated kidney disease.At week 12, treatment with MZE829 drove a 35.6% mean uACR reduction, and 50% of patients achieved a greater than 30% reduction in uACR.Among AMKD patients with focal segmental glomerulosclerosis, uACR fell 61.8% on average, while non-diabetic AMKD patients saw a 48.6% mean reduction from baseline.In the safety-evaluable population , no serious adverse events or severe treatment-related adverse events were observed, and the most common treatment-related adverse events were headache (n=2) and diarrhea (n=2).The company said it expects to continue enrollment and advance MZE829 into a pivotal program, with HORIZON data planned for presentatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDLnyKrn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00BKPKM429.USD","BK4585","NDAQ","BK4112","BK4007","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014013.SGD","LU0314104364.USD","SG9999014039.USD","IE00BN0W2W23.USD","MAZE","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622260027","title":"Maze Therapeutics Inc - to Advance Mze829 to Pivotal Program in Amkd","url":"https://stock-news.laohu8.com/highlight/detail?id=2622260027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622260027?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7PHY8J:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622202724","title":"Maze Therapeutics Inc - 50% of Patients Achieve >30% Uacr Reduction; Mze829 Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2622202724","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622202724?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7PHY8J:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622027287","title":"Maze Therapeutics Announces Positive Topline Data From Phase 2 Horizon Trial of Mze829 Demonstrating the First Clinical Proof-of-Concept in Patients With Broad Apol1-Mediated Kidney Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027287?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA7PHY8J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622027252","title":"Maze Therapeutics Inc Q4 Pretax Profit USD -34.568 Million VS. Ibes Estimate USD -34.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027252?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nPLX99C684:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622027703","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027703","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027703?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436400,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT. Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026. Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors. Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028. \"We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today's positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD,\" said Jason Coloma, Ph.D., chief executive officer of Maze. \"We look forward to advancing MZE829 into a pivotal program and to initiating our two Phase 2 trials of MZE782 in PKU and CKD. As we continu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","MIT","BK4099","FSGS","BK4555","TM","BK4604","03160","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621483757","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 735,106 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2621483757","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621483757?lang=en_us&edition=fundamental","pubTime":"2026-03-21 06:50","pubTimestamp":1774047045,"startTime":"0","endTime":"0","summary":"Harold Bernstein, President, R&D & CMO at Maze Therapeutics, reported transactions in common stock dated 03/20/2026.An option exercise resulted in the acquisition of 15,000 shares at USD 10.42 per share.Sales totaling 6,161 shares were reported at a weighted average price of USD 48.2 per share.Additional sales included 3,795 shares at USD 49.32 per share and 5,044 shares at USD 50.02 per share.Following the reported transactions, Harold Bernstein beneficially owned 0 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL9xy5fn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 735,106 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620234788","title":"Maze Therapeutics Initiated at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2620234788","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620234788?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:24","pubTimestamp":1773829440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 06:24 ET (10:24 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468031","title":"Maze Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468031","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468031?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:36","pubTimestamp":1773664560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 08:36 ET (12:36 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619545716","title":"Wedbush Raises Price Target on Maze Therapeutics to $58 From $43, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545716","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619545716?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:23","pubTimestamp":1773660238,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) has an average rating of buy and mean price target of $58.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":116,"code":"91000000","status":"200"}]}}